Sobi revenues up 27% in 2nd-qtr 2014

Biotech firm Swedish Orphan Biovitrum (SOBI: SS), has announced total revenues of 662.5 million Swedish kronor ($97 million) for the second quarter of 2014, an increase of 27% on figures from the same period last year.

Boost for generics and Orfadin

Product revenues stood at 475.5 million kronor, up from 371.7 million kronor in the same period last year, and Sobi cites revenues for Key Therapeutic Areas as 316.8 million kronor – an increase of 30%. Its genetics and metabolism division had a particular boost from Orfadin (nitisinone), which saw sales go up 68% on second-quarter 2013 to 139.6 million kronor. This increase is largely attributed to Sobi starting direct sales in North America, after  terminating the distribution agreement with Rare Disease Therapeutics from March 31.